# MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment

> **NCT05219734** · — · ACTIVE_NOT_RECRUITING · sponsor: **Invitae Corporation** · enrollment: 400 (estimated)

## Conditions studied

- Cancer
- Solid Tumor
- Non Small Cell Lung Cancer
- Colorectal Cancer
- Bladder Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Personalized Cancer Monitoring (PCM)

## Key facts

- **NCT ID:** NCT05219734
- **Lead sponsor:** Invitae Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-29
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05219734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05219734, "MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05219734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*